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This phase I study was conducted to determine the recommended phase II doses, safety profile, and antitumour activity of a
combination regimen of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours.
Cisplatin and epirubicin were given at fixed doses of 50 and 60mgm
 2, respectively. The irinotecan dose was escalated at 10mgm
 2
increments from a starting dose level of 70mgm
 2. Epirubicin, irinotecan, and their metabolites were measured with HPLC methods.
In all, 35 patients received 141 courses of treatment. Irinotecan dose was escalated in seven cohorts up to 130mgm
 2, and then
finally de-escalated to 110mgm
 2. The dose-limiting toxicity was neutropenic fever. Nonhaematologic toxicities included mild to
moderate nausea/vomiting, diarrhoea and fatigue. Of 34 patients with evaluable disease, one patient had a complete response and
nine patients had partial response, yielding an overall response rate of 29.4%. Pharmacokinetic parameters of epirubicin were not
affected by the sequence of drug administration. However, the AUCs of irinotecan and its metabolites were increased significantly
when irinotecan and epirubicin were administered concurrently. This combination regimen has promising broad antitumour activity,
and will be further evaluated in phase II studies in multiple tumour types.
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DNA topoisomerases I and II are nuclear enzymes that regulate the
torsional strain of supercoiled DNA double helix during critical
cellular processes such as replication, transcription, recombina-
tion, and repair (Stewart et al, 1998; Li and Liu, 2001; Topcu, 2001).
Several antineoplastic agents have been found to exert their
cytotoxic effects by inhibiting topoisomerases. Irinotecan hydro-
chloride (CPT-11; CAMPTOSAR
s), a semisynthetic camptothecin,
is a potent inhibitor of topoisomerase I (Iyer and Ratain, 1998). It
has demonstrated a broad spectrum of antitumour activity and has
become a standard treatment of metastatic colorectal cancer
recently (Saltz et al, 2000; Vanhoefer et al, 2001). Inhibitors of
topoisomerase II include epipodophyllotoxins (e.g. etoposide) and
anthracyclines (e.g. doxorubicin, epirubicin). Topoisomerase
inhibitors bind to and stablise the ‘cleavable’ complex formed
between each topoisomerase enzyme and DNA, with either single-
strand breakage (topoisomerase I) or double-strand breakage
(topoisomerase II), ultimately resulting in cell death when an
advancing DNA replication fork collides into such a complex and
forms fatal breaks (Li and Liu, 2001; Topcu, 2001).
Since both types of topoisomerases are essential in many cellular
processes, it is attractive theoretically to combine topoisomerase I
and II inhibitors (Vasey and Kaye, 1997). Preclinical studies have
shown that crossresistance to both topoisomerase I and II
inhibitors is rare (Tsuruo et al, 1988; Matsuo et al, 1990).
However, laboratory studies have shown conflicting results when
topoisomerase I and II inhibitors were combined. Sequential
administration of topoisomerase I and II inhibitors generally
produces consistent additive or synergistic effects (Bertrand et al,
1991; Kim et al, 1992), whereas with concurrent administration,
both antagonistic and synergistic effects have been observed
depending on the cell line or tumour model studied (D’Arpa et al,
1990; Kaufmann, 1991; Kano et al, 1992; Pei et al, 1997; Eder et al,
1998). These approaches have been evaluated in several phase I/II
clinical studies. Results with sequential administration of topoi-
somerase I and II inhibitors were generally disappointing with
increased toxicities and minimal activity. Interestingly, concurrent
administration of topoisomerase I and II inhibitors have been
found to be active in clinical trials of small-cell lung cancer (SCLC)
(Masuda et al, 1998), non-small-cell lung cancer (NSCLC) (Masuda
et al, 1994; Oshita et al, 1997), and non-Hodgkin’s lymphoma
(NHL) (Saotome et al, 2000; Kancherla et al, 2001). Etoposide is
the topoisomerase II inhibitor administered in most of these
combination studies, while two trials used doxorubicin (Saotome
et al, 2000; Dunphy et al, 2001).
Cisplatin reacts at the N7 position of guanine and adenine
residues to form platinum–DNA adducts, which would lead to cell
death if they are not excised and repaired. Repair of these
platinum–DNA adducts requires unscheduled DNA synthesis.
Topoisomerase inhibitors may, therefore, interfere with this repair
mechanism, resulting in synergistic antitumour activity (Fukuda
et al, 1996; Saltz et al, 1998). A number of phase I/II studies of
irinotecan and cisplatin combination have demonstrated promis-
ing activity in NSCLC (Mori et al, 1997; Kobayashi et al, 1998),
SCLC (Kudoh et al, 1998; Noda et al, 2002), gastric (Boku et al,
1999), oesophageal (Ilson et al, 1999), colorectal (Sato et al, 2001),
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lovarian (Adachi et al, 1999), and cervical cancers (Sugiyama et al,
2000).
It is possible that combining a topoisomerase II inhibitor, such
as epirubicin, with cisplatin and irinotecan would further interfere
with repair of platinum–DNA adducts, resulting in synergistic
activity. Epirubicin, an epimer of doxorubicin, was selected in this
study because it is as effective as doxorubicin at equimolar doses
in advanced breast cancer, but is better tolerated, particularly less
cardiac toxic than doxorubicin (Launchbury and Habboubi, 1993;
Ormrod et al, 1999), and is commonly used in treating gastric
cancer as part of the ECF (epirubicin, cisplatin, and infusional 5-
fluorouracil) regimen (Findlay et al, 1994; Webb et al, 1997). This
potential synergy has not previously been explored in preclinical
or clinical studies.
We hypothesised that a combination chemotherapy regimen
consisting of irinotecan, cisplatin, and epirubicin (PIE regimen)
would have synergistic activity against solid tumours. The current
phase I trial was conducted with the primary objective to
determine the recommended phase II doses and safety profile of
such a combination regimen in patients with advanced solid
tumours. The secondary objective was to assess for preliminary
evidence of antitumour activity in this patient population, and to
evaluate the effect of epirubicin on irinotecan pharmacokinetics
when used in combination.
METHODS
Patient eligibility
Patients were required to have histologically or cytologically
documented advanced solid tumours refractory to conventional
therapy or for whom there are no standard therapies. Eligibility
criteria also included the following: (1) age 18 years or older; (2)
ECOG performance status 0–2; (3) left ventricular ejection fraction
(LVEF) more than 50% by MUGA scan; (4) adequate organ
function with an absolute neutrophil count (ANC)X1.5 10
9l
 1,
platelet count X150 10
9l
 1, total serum bilirubinp1.5 upper
limit of normal (ULN), AST/ALTp3 ULN, and serum
creatininep150mmoll
 1 or calculated creatinine clearance
X60mlmin
 1; and (5) negative pregnancy test for female patients
with child-bearing potential. Radiotherapy was permitted, but
must have been delivered to p25% of the bone marrow, and must
have been completed at least 4 weeks prior to study entry. Full
recovery from radiation-induced toxicities was required. In
addition, patients were required to have received p2 prior
chemotherapy regimens for metastatic disease and must not have
received cytotoxic therapy within 4 weeks of study entry. If prior
chemotherapy contained cisplatin, patients could not have
experienced 4grade 1 residual peripheral neuropathy. For
patients who received prior chemotherapy with anthracyclines,
the cumulative dose had to be p300mgm
 2 of doxorubicin or
equivalent anthracycline dose.
The study protocol was reviewed and approved by the
Institutional Review Board of the Princess Margaret Hospital,
University Health Network. All patients gave written informed
consent before study entry.
Treatment plan
All three drugs were administered sequentially (epirubicin,
followed by cisplatin, followed by irinotecan) on Day 1 every 3
weeks with the exception of Course 2 as described below.
Epirubicin and irinotecan were supplied by Pharmacia Canada
Inc., Mississauga, ON, Canada. Cisplatin (Faulding Canada Inc.,
Montreal, QC, Canada) and epirubicin were given at fixed doses in
this study with epirubicin given at a dose of 60mgm
 2 as an
intravenous bolus, and cisplatin infused over 60min at a dose of
50mgm
 2. Irinotecan was given over 90min immediately after
epirubicin and cisplatin in escalating doses as per protocol. During
Course 2 only, irinotecan was given on Day 1 while epirubicin and
cisplatin were given on Day 3 in order to evaluate possible
pharmacokinetic interactions between irinotecan and epirubicin.
Atropine was administered if diarrhoea, abdominal cramping or
other symptoms of early cholinergic syndrome occurred within 1h
of receiving irinotecan. Diarrhoea and/or abdominal cramping
were treated aggressively with loperamide as recommended
(Abigerges et al, 1994). Dexamethasone and a 5-HT3 antagonist
were administered to all patients as standard premedications
unless contraindicated.
The initial starting dose of irinotecan was 70mgm
 2, and was
escalated by increments of 10mgm
 2 between dose levels.
Successive cohorts of at least three patients were treated at each
dose level. If any of the first three patients experienced dose-
limiting toxicities (DLT) at a dose level, three additional patients
were enrolled to that dose level. If no more than one of six patients
experienced DLT, then the next cohort of patients was treated at
the next higher dose level. If two or more patients at any dose level
experienced DLT, then that dose level was considered to have
exceeded the maximum tolerated dose (MTD), and the dose level
immediately preceding that was designated as the MTD (equivalent
to the recommended phase II dose). An additional three patients
were then enrolled at the MTD to further assess safety and side
effects. Intrapatient dose escalation was not allowed.
Toxicities were assessed using the National Cancer Institute
(NCI) common toxicity criteria (CTC, version 2.0). DLT was
defined as any first course, Xgrade 3 nonhaematologic toxicity
except alopecia or inadequately controlled nausea and vomiting,
Xgrade 3 diarrhoea despite aggressive loperamide treatment,
grade 4 neutropenia with fever, grade 4 thrombocytopenia, or dose
delay of 42 weeks due to drug-related toxicity.
Patients were required to have an ANC X1.5 10
9l
 1, platelet
count X100 10
9l
 1, and full resolution of gastrointestinal
toxicities before initiation of each treatment course. The irinotecan
dose was reduced by one dose level (10mgm
 2) for all subsequent
treatment courses if a patient experienced grade 4 neutropenia,
grade 3 thrombocytopenia, or grade 3 nonhaematologic toxicity in
the previous treatment cycle. If a patient experienced neutropenic
fever, grade 4 thrombocytopenia, or any grade 4 nonhaematologic
toxicity in the previous treatment cycle, the irinotecan dose was
reduced by two dose levels (20mgm
 2). Patients who experienced
significant toxicity despite dose reduction by two levels were
discontinued from the study. Growth factor support was not
allowed on this study.
Specimen collection and pharmacokinetic analysis
Heparinised venous blood samples were drawn at 0, 45, 90min
from the beginning of irinotecan infusion, then at 15, and 30min
and 1, 2, 4, 6, 8, 24, and 48h after the end of irinotecan infusion;
and at 0, 5, 15, 30, 60min from the beginning of epirubicin
infusion, then at 2, 4, 8, 24, and 48h after the end of epirubicin
infusion. Samples were centrifuged immediately at room tempera-
ture, and plasma was separated and stored in aliquots at  201C
until analysis.
Irinotecan, SN-38 and APC concentrations were determined
using a high-performance liquid chromatography assay. Plasma
samples were mixed with an internal standard (camptothecin) in
acidified acetonitrile to precipitate plasma proteins, then incu-
bated for 15min at 401C to convert analytes to their respective
lactone forms. After addition of triethylamine (TEA) buffer (pH
4.2), samples were centrifuged and supernatants were transferred
to an amber vial for injection (60ml) onto of a Zorbax-SB-C8
column (MacMod Analytical Inc., Chadds Fords, PA, USA) with a
mobile phase of acetonitrile:0.025 M TEA buffer (pH 4.2)
(25:75%). The fluorescence detector was operated at an excitation
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lwavelength of 372nm, irinotecan and APC were monitored at an
emission wavelength of 425nm, while SN-38 and the internal
standard were monitored at 535nm. SN-38 glucuronide (SN-38G)
concentrations were estimated as increases in SN-38 concentra-
tions after incubation of plasma samples with b-glucuronidase.
The lower limits of quantitation for irinotecan, SN-38, and APC
were 1.28, 0.48 and 0.96ngml
 1, respectively.
For analysis of epirubicin and epirubicinol, plasma samples
were mixed with an internal standard (daunorubicin) and 1ml of
0.02 M sodium biphosphate buffer (pH 4.0). Samples were added to
C8 solid-phase extraction tubes and extracts were dried on an
evaporator. They were reconstituted in the mobile phase of
acetonitrile : 0.02 M sodium phosphate buffer (pH 2.5) (33:67%),
and injected onto a C18 column (Phenomenex, Torrance, CA,
USA). The fluorescence detector was set at excitation 480nm and
emission 560nm. The lower limit of quantitation for both
epirubicin and epirubicinol was 5ngml
 1.
Pharmacokinetic parameters were determined by noncompart-
mental methods using WinNonlin (Version 3.0, Pharsight Corp.,
Mountain View, CA, USA). Since irintotecan pharmacokinetics is
known to be linear for doses up to 180mgm
 2 (Mathijssen et al,
2001), area under the concentration vs time curve (AUC) was dose
standardised. Pharmacokinetic parameters were compared using
the paired t-test. A probability of Po0.05 was considered
significant. The program S-PLUS for Windows (Version 6)
(Insightful Corp., Seattle, WA, USA) was used for statistical
analysis.
Evaluations at baseline and during treatment
At study entry, baseline evaluations included complete medical
history and physical examination, chest X-ray, ECG, MUGA scan,
and radiological imaging of assessable disease. Routine laboratory
evaluations including complete blood counts (CBCs) with differ-
ential and biochemical profiles were performed at the start of every
treatment cycle. CBC with differential was repeated weekly
throughout the study.
Radiological imaging was repeated every 6 weeks to assess
tumour response until disease progression, completion of study
treatment, or discharge of patient from the study. Tumour
responses were assessed according to standard WHO criteria.
MUGA scan was repeated prior to each course once the
cumulative dose of epirubicin exceeded 360mgm
 2. In patients
who achieved an objective response or stable disease status
without intolerable toxicity, up to eight courses of treatment could
be given.
RESULTS
Patient characteristics
In all, 35 patients received treatment on this study from October
1999 to 2001. Patient characteristics are summarised in Table 1.
The median age was 53 years (range: 34–69 years). In total, 18 men
and 17 women were enrolled in the study. Of the patients, 94% had
performance status of ECOG 0 or 1. Enrolled patients had primary
tumours originating from a large variety of sites, the majority of
which were from the gastrointestinal (51.4%) or gynaecological
tract (22.9%). A total of 15 patients had received prior
chemotherapy (10 patients one prior chemotherapy regimen, four
patients two prior chemotherapy regimens, and one patient two
prior chemotherapy regimens for metastatic disease and one prior
adjuvant chemotherapy regimen), one patient had received prior
radiation therapy, and four had received both therapeutic
modalities. Of these, 15 patients were chemotherapy naı ¨ve.
Determination of recommended phase II doses
The first three patients were treated at the initial dose level of
irinotecan at 70mgm
 2, and all three patients tolerated the
treatment well without DLT. At the second dose level of irinotecan
at 80mgm
 2, one of the initial three patients enrolled at this dose
level developed neutropenic fever during Course 1. Three
additional patients were enrolled to this dose level, and one
developed grade 3 diarrhoea, uncomplicated grade 4 neutropenia,
and grade 4 thrombocytopenia. On review, the two patients with
significant haematologic toxicity were both found to have slightly
elevated baseline total serum bilirubin levels of 1.2 times, and 1.5
times ULN, respectively. Both of these patients had mild
obstruction of hepatobiliary tracts due to disease (one with
cholangiocarcinoma, and the other one with cervical cancer with
metastases to the pancreas), which accounted for hyperbilirubi-
naemia. Two additional patients with normal baseline total serum
bilirubin levels tolerated the 80mgm
 2 dose level without any
DLT. Hence, of six patients with normal baseline total serum
bilirubin levels who were treated at the irinotecan dose of
80mgm
 2, none developed DLT. Therefore, further enrollment
was restricted to patients with normal total serum bilirubin levels.
No DLTs were observed until irinotecan dose was escalated to
130mgm
 2.
At an irinotecan dose level of 130mgm
 2, one of the first three
patients developed neutropenic fever during course 1, and one of
two additional patients treated at that expanded dose level also
developed neutropenic fever during Course 1. Therefore, the
irinotecan dose was subsequently de-escalated. Three more
patients were enrolled and treated at an irinotecan dose level of
120mgm
 2, two of these additional patients developed neutro-
penic fever during Course 1. The irinotecan dose was further de-
escalated to 110mgm
 2, and three more patients were treated at
this expanded dose level. No DLT was seen, and irinotecan at
Table 1 Patient characteristics
Characteristic Patients no. (n¼35) %
Age (years)
Median 53
Range 34–69
Sex
Male 18 51.4
Female 17 48.6
Performance status, ECOG
0 14 40.0
1 19 54.3
2 2 5.7
Tumour type
Gastric 10 28.6
Ovary 5 14.3
Unknown primary 5 14.3
Cervix 3 8.6
Bilary tract, hepatocellular 3 8.6
GIST 2 5.7
Small bowel 2 5.7
Oesophageal 2 5.7
Others
a 3 8.6
Prior therapy
Chemotherapy 15 42.9
Radiation therapy 1 2.8
Both chemotherapy and radiation therapy 4 11.4
None 15 42.9
aOne of each of pancreas, lung, and head and neck cancers.
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 2 every 3 weeks in combination with epirubicin
60mgm
 2, and cisplatin 50mgm
 2 was selected as the recom-
mended phase II doses for this triple combination.
The actual study dose-escalation scheme is shown in Table 2. A
total of 141 courses of treatment were given, and the median
number of course administered per patient was four with a range
of one to eight. Out of 141 treatment courses, there were 45
episodes of treatment delays alone, 10 episodes of dose reduction
alone, 21 episodes of both treatment delay and dose reduction, and
one episode of cancelled treatment. Irinotecan received-to-
intended dose intensity ratios ranged from 71.1 to 96.1%. Over
80% of the intended irinotecan dose was administered at all dose
levels except at the highest two doses levels. At the recommended
phase II dose level, the irinotecan received-to-intended dose
intensity ratio was 86.4%.
Toxicities
Overall, toxicities observed in this study were those expected from
a combination of these three cytotoxic agents. Selected toxicities
are summarised in Tables 3 and 4. Grade 3/4 haematologic
toxicities included neutropenia in 29 patients (51.8% of all
treatment courses); anaemia in nine patients (9.9% of all treatment
courses), six of whom required transfusion of packed red blood
cells; and thrombocytopenia in five patients (9.2% of all treatment
courses), one of whom required transfusion of platelets. Five
patients had seven episodes of neutropenic fever throughout their
entire duration of study therapy, and all neutropenic fever
episodes resolved with parenteral antibiotics treatment. No grade
4 nonhaematologic toxicities were observed in this study. Grade 3
nonhaematologic toxicities included fatigue, nausea, vomiting, and
diarrhoea. However, these events were infrequent, occurring in
p10% treatment courses. Of note, no patient experienced grade 4
diarrhoea and only two patients experienced grade 3 diarrhoea
during Course 1. There were no cases of treatment-related death.
No clinically significant changes in LVEF on MUGA scans or
development of symptomatic congestive heart failure were seen in
any patients on this study.
Antitumour activity
Response was not the primary end point of this phase I study;
however, promising antitumour activity was observed. In all, 34
patients were evaluable for tumour response. The one none-
valuable patient had gastric carcinoma with ascites and peritoneal
carcinomatosis as the only sites of disease. Overall, 10 patients
Table 3 Summary of haematologic toxicities (for first and all courses)
First course grade 3/4 toxicity Overall grade 3/4 toxicity (patient/course)
Dose level (mgm
 2) Total no. of patients/courses Neutropenia Thrombocytopenia Anaemia Neutropenia Thrombocytopenia Anaemia
70 3/16 0 0 0 2/6 1/3 0
80 8/23 6 1 1 8/20 2/5 2/5
90 4/13 2 0 0 2/6 0 0
100 3/7 3 0 0 3/5 0 0
110 3/18 2 0 0 3/7 0 0
120 3/18 2 0 0 2/3 0 1/1
130 5/24 4 0 2 4/15 1/2 4/6
120
a 3/11 3 1 0 3/9 1/3 1/1
110
a 3/11 1 0 0 2/2 0 1/1
aIrinotecan dose was reduced to this level due to DLTs seen at higher doses.
Table 4 Summary of non-haematologic toxicities (for first and all courses)
First course grade 3/4 toxicity Overall grade 3/4 toxicity (patient/course)
Dose level (mgm
 2) Total no. of patients/courses Nausea/vomiting Diarrhoea Fatigue Nausea/vomiting Diarrhoea Fatigue
70 3/16 0 1 1 0 1/1 1/1
80 8/23 1 1 1 1/1 1/1 1/1
90 4/13 2 0 2 3/5 0 2/4
100 3/7 0 0 0 1/1 1/1 0
110 3/18 0 0 0 1/1 0 0
120 3/18 2 0 0 2/3 0 1/1
130 5/24 1 0 1 1/1 0 1/1
120
a 3/11 0 0 0 0 0 0
110
a 3/11 0 0 0 0 0 0
aIrinotecan dose was reduced to this level due to DLTs seen at higher doses.
Table 2 Dose-escalation schedule and number of patients
Dose level
(mgm
 2)
No. of
patients
No. of
courses
No. of patients
with DLT/ total no.
of patients treated at
that dose level
Irinotecan dose
intensity
(administered/
intended) (%)
70 3 16 0/3 88.3
80 8 23 2/8 83.3
90 4 13 0/4 88.2
100 3 7 0/3 96.1
110 3 18 0/3 88.1
120 3 18 0/3 86.4
130 5 24 2/5 78.9
120 3 11 2/3 71.1
110 3 11 0/3 83.5
Total 35 141
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95% CI: 0–8.5%), and nine partial responses (26.5%, 95% CI:
11.7–41.2%). The duration of response in the one patient with
complete response was 7.3 months, and the median duration of
response among the nine patients with partial responses was 5.7
months. One patient with jejunal adenocarcinoma demonstrated a
complete response and received eight cycles of treatment. The
other nine responding patients included three patients with gastric
or gastro-oesophageal junction adenocarcinoma, three with
squamous cell carcinoma of the cervix, one with ovarian cancer,
one with hepatocellular carcinoma, and one with cancer of
unknown primary. Among the 10 patients who had a response,
three patients had received prior chemotherapy and radiation
therapy, and two patients each received prior chemotherapy or
radiation therapy. In addition, the patient with gastric adenocar-
cinoma who was not assessable for response had improvement in
his peritoneal carcinomatosis and resolution of ascites after two
cycles of treatment. He was progression free for 4 months and after
disease progression, was retreated with the study regimen, and
again remained progression free for eight additional months.
Furthermore, 13 patients had stable disease, and had a median of
four courses of treatment.
Pharmacokinetics
Complete pharmacokinetic data for both Course 1 and Course 2
were available in 29 patients for irinotecan, and in 12 patients for
epirubicin. Pharmacokinetic parameters of irinotecan, epirubicin,
and their metabolites are summarised in Tables 5 and 6. Mean
plasma irinotecan concentrations were plotted in Figure 1.
Pharmacokinetic parameters of epirubicin were not affected by
the sequence of drug administration (Table 5). However, when
administered immediately after epirubicin, irinotecan AUCt and
AUCinf increased significantly from 2870 and 2958 to 3261 and
3404nghml
 1, respectively. Similarly, AUCs for SN-38, SN-38G,
total SN-38, and APC all increased significantly (Table 6).
However, total body clearance, volume of distribution and t1/2
Table 6 Pharmacokinetic parameters of irinotecan
Sequence
Parameter Irinotecan+epirubicin Irinotecan-epirubicin P-value
AUCt (nghml
 1)
a 326171563
b 28707916 0.03
AUCinf (nghml
 1)
a 340471761 295871018 0.02
CL (lh
 1) 35.8714.7 37.1710.6 0.4
Vd (l) 5327247 5747160 0.3
t1/2 (h) 10.673.3 10.972.1 0.5
SN-38 AUCt (nghml
 1)
a 102754 78736 o0.001
SN-38G AUCt (nghml
 1)
a 5587480 3787223 0.005
Total SN-38 AUCt (nghml
 1)
a 6627516 4677244 0.004
APC AUCt (nghml
 1)
a 11447866 7257460 0.001
AUC SN-38/AUC irinotecan 0.03270.01 0.02770.01 0.002
AUC SN-38G/AUC SN-38 5.572.9 5.172.1 0.3
AUC APC/AUC irinotecan 0.3570.24 0.2570.12 0.003
AUCt¼area under the curve to last measurable concentration; AUC0–p¼area under the curve extrapolated to infinity;
CL¼total body clearance; Vd¼apparent volume of distribution; t1/2¼elimination half-life.
aDose standardised to 100mg
irinotecan.
bValues are expressed as means 7s.d.
Table 5 Pharmacokinetic parameters of epirubicin
Sequence
Parameter Irinotecan+epirubicin Irinotecan-epirubicin P-value
AUCt (nghml
 1)
a 7837356
b 7237296 0.7
AUCinf (nghml
 1)
a 10327370 9107368 0.5
CL (lh
 1) 110742 125745 0.4
Vd (l) 347771937 256371122 0.08
t1/2 (h) 23.1710.8 16.077.8 0.07
Epi-ol AUCt (nghml
 1)
a 9217634 7887482 0.5
AUCt¼area under the curve to last measurable concentration; AUC0–p¼area under the curve extrapolated to infinity;
CL¼total body clearance; Vd¼apparent volume of distribution; t1/2¼elimination half-life.
aDose standardised to 100mg
epirubicin.
bValues are expressed as means 7s.d.
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Figure 1 Dose standardised mean plasma irinotecan concentrations in
Course 1 (administered immediately after epirubicin) and Course 2
(administered 2 days before epirubicin).
Phase I study of irinotecan, cisplatin, epirubicin
X Chen et al
621
British Journal of Cancer (2003) 89(4), 617–624 & 2003 Cancer Research UK
C
l
i
n
i
c
a
lof irinotecan were not affected by coadministration with
epirubicin.
At the irinotecan dose level of 80mgm
 2, one patient developed
neutropenic fever, and one of the additional three patients enrolled
at this dose level also developed prolonged neutropenia, grade 3
thrombocytopenia and grade 3 diarrhoea. These two patients were
found to have elevated bilirubin levels at 1.2 and 1.5 times ULN.
The ratio of epirubinol AUC to epirubicin AUC in Course 1 was
7 that in Course 2 in the first patient. This patient developed
neutropenic fever again on Course 2, although irinotecan dose was
reduced, and bilirubin returned to normal. The second patient had
the highest epirubicin, epirubinol, SN-38G, total SN-38, and APC
AUCs in the study. Furthermore, compared to Course 2, SN-38G,
total SN-38, and APC AUCs in Course 1 were 460% higher. This
patient’s bilirubin improved to normal, and she underwent four
more courses of treatment with reduced irinotecan dose without
any complication.
DISCUSSION
The current phase I study was conducted to assess the feasibility of
combining irinotecan, cisplatin, and epirubicin in an every-3-week
schedule; the recommended phase II doses and side effects of this
three-drug combination. This combination was conceived based
on different mechanisms of antitumour activity of these agents,
synergistic effects between irinotecan and cisplatin seen in
preclinical studies, and broad efficacy of the irinotecan and
cisplatin combination demonstrated in phase I/II clinical studies
with multiple tumour types. Different and nonoverlapping toxicity
profiles of these agents further support such a combination.
The two patients with elevated bilirubin levels treated at the
irinotecan dose level of 80mgm
 2 provide an interesting insight
into the potential role of biliary excretion in the elimination of
epirubicin, irinotecan, and their metabolites. Irinotecan is
converted to its active metabolite, SN-38, by the enzyme
carboxylesterase. However, less than 10% of the administered
irinotecan dose is converted to SN-38 (Slatter et al, 2000), which is
further glucuronidated by the enzyme UGT1A1 to SN-38G and
excreted via the biliary tract. Irinotecan-induced myelosuppres-
sion has been found to correlate with the plasma SN-38 exposure,
as measured by the AUC. Over 60% of irinotecan and its
metabolites are excreted via the biliary tract. Epirubicin is
converted into several metabolites, including epirubicinol. Glucur-
onides of epirubicin and epirubincinol are subsequently excreted
via the biliary tract. Impaired biliary excretion due to obstruction
likely contributed to the DLT seen in these two patients.
Enrollment of subsequent patients on study was restricted to
patients with normal baseline total serum bilirubin levels, and no
further DLT was observed until the irinotecan dose was escalated
to 130mgm
 2. Therefore, it is possible that in patients with even
mildly elevated bilirubin, biliary elimination of irinotecan,
epirubicin and their glucuronide metabolites could be impaired,
resulting in increased toxicity. Indeed, baseline plasma bilirubin
and alkaline phosphatase levels have recently been found to
correlate with irinotecan exposure and clearance (Raymond et al,
2002).
Pharmacokinetic interactions between irinotecan and other
anticancer agents have been investigated in clinical studies of
combination chemotherapy. No interaction was seen in majority of
these studies (Saltz et al, 1996; Wasserman et al, 1999; Adjei et al,
2000; de Jonge et al, 2000b). The AUCs of both irinotecan and SN-
38 were found to be lower when given together with carboplatin,
suggesting increased clearance of irinotecan (Okamoto et al, 1998).
In another study, the AUCs of both irinotecan and SN-38 were
increased when given together with paclitaxel. However, the
mechanism of this interaction was attributed to the paclitaxel
vehicle, Cremophor EL (Yamamoto et al, 1999). In the present
study, AUCs of irinotecan and its metabolites were significantly
higher when administered immediately after epirubicin. In
contrast, SN-38 AUC is not increased when irinotecan is
coadministered with doxorubicin (Dunphy et al, 2001). Further-
more, ratios of SN-38 AUC to irinotecan AUC, and APC AUC to
irinotecan AUC were also significantly higher, while that of SN-
38G AUC to SN-38 AUC did not differ when irinotecan and
epirubicin were administered on the same day. Total body
clearance, volume of distribution, and t1/2 of irinotecan were not
affected by epirubicin. Epirubicin pharmacokinetic parameters
were not affected by the sequence of drug administration. One
possible explanation is that epirubicin and its metabolites
competitively inhibit biliary excretion of irinotecan and its
metabolites. Therefore, irinotecan and epirubicin should only be
administered concurrently after careful phase 1 studies to avoid
potentially increased toxicities due to pharmacokinetic interaction
between these two drugs.
The DLT in this study was neutropenic fever. Grade 3 or 4
neutropenia was the most common haematologic toxicity ob-
served, with incidence ranging from 17 to 87% of treatment
courses at various irinotecan dose levels. Even with the high
incidence of neutropenia, the rate of neutropenic fever was low at
5% of treatment courses. Grade 3 or 4 thrombocytopenia and
anaemia were seen in 9.2% and 9.9% of treatment courses,
respectively.
No grade 4 diarrhoea was seen in this study, and grade 3
diarrhoea was rare at 2.1% of chemotherapy courses. This rate of
grade 3 diarrhoea was consistent with rates reported in prior
studies combining irinotecan and cisplatin (Saltz et al, 1998; de
Jonge et al., 2000a). The lower frequency of grade 3/4 late
diarrhoea in these three studies contrasts with the frequency of
420% grade 3/4 late diarrhoea observed in single-agent studies
of CPT-11 administered on a weekly or every-3-week regimen and
is presumably related to the lower CPT-11 doses when given in
combination (Vanhoefer et al, 2001).
As expected, the combination of cisplatin, irinotecan, and
epirubicin had antitumour activity in a variety of tumour types.
One patient with jejunal adenocarcinoma had a complete response,
and nine other patients had partial responses. With its broad
spectrum of antitumour activity, this combination regimen would
be worth further evaluation in multiple tumour types. Specifically,
it will be further assessed in gastric or gastro-oesophageal junction
carcinomas, in view of the demonstrated activity of the ECF
regimen, as well as the irinotecan and cisplatin combination. The
advantage of the PIE regimen is combining three of the most active
agents against this malignancy while attempting to eliminate the
inconvenience of infusional 5-FU.
Preclinical studies suggested synergistic effects on sequential
administration of topoisomerase I and II inhibitors (Bertrand et al,
1991; Kim et al, 1992), but results from several phase II studies
using this approach were disappointing with increased toxicities
and no enhanced therapeutic efficacy (Ando et al, 1997; Herben
et al, 1997). On the other hand, both synergistic and antagonistic
effects have been reported when topoisomerase I and II inhibitors
were administered concurrently in laboratory models (Pei et al,
1997; Eder et al, 1998). The results from our study are consistent
with other studies of concurrent administration of topoisomerase I
and II inhibitors, where encouraging antitumour activity has been
reported in multiple tumour types (Masuda et al, 1994, 1998;
Oshita et al, 1997; Saotome et al, 2000). The observed antitumour
activity seen in this study might also be explained by the addition
of cisplatin, and the use of epirubicin instead of etoposide as in
most previous studies. Epirubicin, unlike etoposide, is not a pure
topoisomerase II inhibitor, it also exerts its antitumour effects
through other mechanisms such as free-radical generation and
DNA intercalation.
In conclusion, the DLT in this phase I combination study of
irinotecan, cisplatin, and epirubin (PIE regimen) administered
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levery 3 weeks was neutropenic fever. The recommended doses for
phase II studies are irinotecan 110mgm
 2, cisplatin 50mgm
 2,
and epirubicin 60mgm
 2 on Day 1 with irinotecan administered
immediately after epirubicin every 3 weeks in patients with good
performance status and normal total serum bilirubin levels. The
parabolic dose escalation encountered in this study suggests that
the dose–effect relationship of this regimen is very steep, and the
recommended phase II doses are unlikely generalisable for patients
with poor performance status and abnormal hepatic function.
Based on antitumour responses seen in this study, phase II studies
of this combination in metastatic gastric cancer and cervical
cancer have been initiated. In addition, further evaluation of
optimal doses of this regimen in patients with mild liver
dysfunction is ongoing to determine how best to modify doses
in this special patient population.
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